Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
AM095
Cat. No.:
OB0225LY-0080
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
AM095 is a small molecule compound that shows potential in neuroprotection and anti-inflammation, especially for neurodegenerative diseases.
Synonym:
1345614-59-6; AM095; AM095 sodium; AM-095; Sodium, 2-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]acetate; Sodium (R)-2-(4'-(3-methyl-4-(((1-phenylethoxy)carbonyl)amino)isoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetate; Sodium {4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetate
CAS No.:
1345614-59-6
Compound CID:
53303875
Formula:
C27H23N2NaO5
Formula Weight:
478.47
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
AM095 can be used as a potent LPA1 receptor antagonist for recombinant human or mouse LPA1 respectively.
Library Information
Targets:
LPA receptor
Receptors:
LPA1
Pathways:
GPCR/G protein
Plate Number:
AOCL-2
Plate Location:
a3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
5.5 mg/mL; 11.49 mM
